Openbookopenbook
Equity
NIOX Group PLC(NIOX)
GBX --+0.00%
Reward55Moderate
Risk23Low
📊75%Data
2.0% dividend yield · Revenue growing 20% YoY
NIOX
+0.0 · +0.00%
GBX · LSE
NIOX Group PLC | Healthcare
Defensive Anchor
Market Cap:266.64M
ℹ️
Reward Rating
55
Moderate
Bottom 50% (model universe)
75% data coverage
ℹ️
Risk Rating
23
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on NIOX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: 83p.

What is NIOX Group PLC?

NIOX Group Plc engages in the design, development, and commercialization of medical devices for asthma diagnosis, monitoring, and management worldwide.

NIOX · Verdict

Solid reward · low risk

NIOX stands out on cash flow and balance sheet, but watch the valuation signal.

Based on 88% data coverage

NIOX · Verdict

What’s working & what to watch

Strengths 3

  • Cash flow87/100

    39% free-cash-flow margin

  • Balance sheet82/100

    Interest covered 40.0×

  • Volatility75/100

    Above average

Watchouts 1

  • Valuation39/100

    P/E 57.5× · PEG 4.42

Model-based scoring. For information only — not financial advice.

What is NIOX Group PLC?

NIOX Group Plc engages in the design, development, and commercialization of medical devices for asthma diagnosis, monitoring, and management worldwide. It offers NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device and a range of consumables, including sensors, individual disposable mouthpieces, and breathing handles for the measurement of Fractional Exhaled Nitric Oxide (FeNO) level in patients. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 266.64M, and a P/E ratio of 63.8x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (55)

The scoring profile indicates moderate reward potential, with profitability and growth as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap266.64M
P/E Ratio63.8
Dividend Yield2.03%
52 Week High77.6
52 Week Low52.4464
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares Outstanding418M
No. of Employees91
IndustryMedical Devices
ExchangeLSE
Beta-0.216
CurrencyGBX · Reports in GBP
Websitewww.niox.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.